Difference between revisions of "Part:BBa K3117039"
(→MIT MAHE 2020) |
|||
| Line 6: | Line 6: | ||
Part BBa_K3117039 is the constant part of the light chain within an antibody. Together with the single chain variable fragment, the kappa-light chain forms the variable light chain of an antibody. Additionally, the kappa-light chain binds to the constant region 1 (<partinfo>BBa_K3117040</partinfo>) of an antibody via disulfid bonds. | Part BBa_K3117039 is the constant part of the light chain within an antibody. Together with the single chain variable fragment, the kappa-light chain forms the variable light chain of an antibody. Additionally, the kappa-light chain binds to the constant region 1 (<partinfo>BBa_K3117040</partinfo>) of an antibody via disulfid bonds. | ||
| − | == | + | ==MIT_MAHE 2020== |
'''Summary''' | '''Summary''' | ||
Latest revision as of 18:15, 23 October 2020
kappa light chain
Usage and Biology
Part BBa_K3117039 is the constant part of the light chain within an antibody. Together with the single chain variable fragment, the kappa-light chain forms the variable light chain of an antibody. Additionally, the kappa-light chain binds to the constant region 1 (BBa_K3117040) of an antibody via disulfid bonds.
MIT_MAHE 2020
Summary
Kappa light chain is the constant part of the light chain within an antibody. Together with the single chain variable fragment, the kappa-light chain forms the variable light chain of an antibody. Additionally, the kappa-light chain binds to the constant region 1 of an antibody via disulfide bonds.
References
1. Vincent Rajkumar S. (2014). Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. American journal of hematology, 89(10), 999–1009. https://doi.org/10.1002/ajh.23810
2. Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., Jagannath, S., … Miguel, J. F. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology, 15(12), e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
3. Chen, J., Fang, M., Zhao, Y. P., Yi, C. H., Ji, J., Cheng, C., Wang, M. M., Gu, X., Sun, Q. S., Chen, X. L., & Gao, C. F. (2015). Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma. PloS one, 10(6), e0127022. https://doi.org/10.1371/journal.pone.0127022
4. Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: a cancer journal for clinicians, 64(1), 9–29. https://doi.org/10.3322/caac.21208 "